You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 25, 2024

GLYSET Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Glyset, and what generic alternatives are available?

Glyset is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in GLYSET is miglitol. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the miglitol profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Glyset

A generic version of GLYSET was approved as miglitol by WESTMINSTER PHARMS on February 24th, 2015.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GLYSET?
  • What are the global sales for GLYSET?
  • What is Average Wholesale Price for GLYSET?
Summary for GLYSET
Drug patent expirations by year for GLYSET
Drug Prices for GLYSET

See drug prices for GLYSET

US Patents and Regulatory Information for GLYSET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer GLYSET miglitol TABLET;ORAL 020682-001 Dec 18, 1996 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer GLYSET miglitol TABLET;ORAL 020682-002 Dec 18, 1996 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer GLYSET miglitol TABLET;ORAL 020682-003 Dec 18, 1996 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for GLYSET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer GLYSET miglitol TABLET;ORAL 020682-001 Dec 18, 1996 ⤷  Sign Up ⤷  Sign Up
Pfizer GLYSET miglitol TABLET;ORAL 020682-003 Dec 18, 1996 ⤷  Sign Up ⤷  Sign Up
Pfizer GLYSET miglitol TABLET;ORAL 020682-002 Dec 18, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for GLYSET

See the table below for patents covering GLYSET around the world.

Country Patent Number Title Estimated Expiration
U.S.S.R. 1087074 PROCESS FOR PREPARING DERIVATIVES OF 3,4,5-TRIOXYPIPERIDINE ⤷  Sign Up
Italy 7827067 ⤷  Sign Up
Denmark 285084 ⤷  Sign Up
Norway 154918 ⤷  Sign Up
Ireland 47070 NEW DERIVATIVES OF 3,4,5-TRIHYDROXY PIPERIDINE, PROCESSES FOR THEIR PRODUCTION AND MEDICAMENTS AND ANIMAL FEEDS CONTAINING THEM ⤷  Sign Up
Austria A533181 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for GLYSET

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0266730 98C0014 Belgium ⤷  Sign Up PRODUCT NAME: MIGLITOL; NAT. REGISTRATION NO/DATE: NL 22 138 19970204; FIRST REGISTRATION: NL - 19 343 UR 19960723
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.